지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
In KORUS FTA negotiations, the following issues may be raised, among others:
<Drug Expenditure Rationalization Plan>
-whether to encourage, and how to encourage, research and development of innovation and IPR protection of pharmaceuticals
-whether to apply pharmacoeconomic evaluation to generic drugs
-how to recognize the value of the innovative pharmaceuticals in the amount of reimbursement
-whether to permit manufacturers to apply for an increased amount of reimbursement after a decision on a reimbursement amount is made
-whether to ensure that the reimbursement amounts are inflation-adjusted
-how to guarantee transparency of DERP:
publish in advance any measures
provide interested persons opportunities to comment
complete consideration of approvals within a specified time
disclose procedural rules, methodologies, principles, and criteria
make available an independent review body to review determinations
-whether to permit a pharmaceutical manufacturer to disseminate to health professionals and consumers through the manufacturer’s Internet site and on other linked sites information regarding its products
-How to encourage ethical business practices
<MRA>
-Mutual Recognition Agreement on the Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) inspection of pharmaceuticals within specified period of time
-Mutual Recognition of Marketing approval of generic drugs
<Biogenerics>
-Development of regulations related to the approval of biogenerics within specified period of time
<Committee>
-Whether to establish a technical committee or working group and its scope of authority
<IPR Protection>
-scope of guaranteeing data exclusivity
-whether to permit linkage between patent and marketing approval
-whether to permit use of patented product to generate information necessary to support an application for marketing approval (Bolar provision)
-whether to allow adjustment of patent term to compensate unreasonable delay in marketing approval procedure
-scope of compulsory licensing
For a successful conclusion of negotiations, a package deal among the above core issues is necessary. Given the political sensitivity and high priority of DERP to Korea and its national interest, Korea must make certain concessions in IPR issues and Committee issues in order to accomplish its policy aims regarding DERP. Also, it must be considered that enhance protection of IPR may give certain incentives of R&D for Korean drug manufacturers who need a long-term business strategy of development. Although MRA and Biogenerics are ambitious proposals by Korea, they are susceptible to an unbalance-of-benefit claim by the United States because those proposals are focused on trade in generic (not original) drugs. In order to avoid a situation where drug issues are compelled to be traded with other unsolved controversial issues in other sectors at the last phase of negotiations, both sides must make sincere efforts to reach an early agreement through practical gives-and-takes.
In KORUS FTA negotiations, the following issues may be raised, among others: <Drug Expenditure Rationalization Plan> -whether to encourage, and how to encourage, research and development of innovation and IPR protection of pharmaceuticals -whether to apply pharmacoeconomic evaluation to generic drugs -how to recognize the value of the innovative pharmaceuticals in the amount of reimbursement -whether to permit manufacturers to apply for an increased amount of reimbursement after a decision on a reimbursement amount is made -whether to ensure that the reimbursement amounts are inflation-adjusted -how to guarantee transparency of DERP: publish in advance any measures provide interested persons opportunities to comment complete consideration of approvals within a specified time disclose procedural rules, methodologies, principles, and criteria make available an independent review body to review determinations -whether to permit a pharmaceutical manufacturer to disseminate to health professionals and consumers through the manufacturer’s Internet site and on other linked sites information regarding its products -How to encourage ethical business practices <MRA> -Mutual Recognition Agreement on the Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) inspection of pharmaceuticals within specified period of time -Mutual Recognition of Marketing approval of generic drugs <Biogenerics> -Development of regulations related to the approval of biogenerics within specified period of time <Committee> -Whether to establish a technical committee or working group and its scope of authority <IPR Protection> -scope of guaranteeing data exclusivity -whether to permit linkage between patent and marketing approval -whether to permit use of patented product to generate information necessary to support an application for marketing approval (Bolar provision) -whether to allow adjustment of patent term to compensate unreasonable delay in marketing approval procedure -scope of compulsory licensing For a successful conclusion of negotiations, a package deal among the above core issues is necessary. Given the political sensitivity and high priority of DERP to Korea and its national interest, Korea must make certain concessions in IPR issues and Committee issues in order to accomplish its policy aims regarding DERP. Also, it must be considered that enhance protection of IPR may give certain incentives of R&D for Korean drug manufacturers who need a long-term business strategy of development. Although MRA and Biogenerics are ambitious proposals by Korea, they are susceptible to an unbalance-of-benefit claim by the United States because those proposals are focused on trade in generic (not original) drugs. In order to avoid a situation where drug issues are compelled to be traded with other unsolved controversial issues in other sectors at the last phase of negotiations, both sides must make sincere efforts to reach an early agreement through practical gives-and-takes.
In KORUS FTA negotiations, the following issues may be raised, among others: <Drug Expenditure Rationalization Plan> -whether to encourage, and how to encourage, research and development of innovation and IPR protection of pharmaceuticals -whether to apply pharmacoeconomic evaluation to generic drugs -how to recognize the value of the innovative pharmaceuticals in the amount of reimbursement -whether to permit manufacturers to apply for an increased amount of reimbursement after a decision on a reimbursement amount is made -whether to ensure that the reimbursement amounts are inflation-adjusted -how to guarantee transparency of DERP: publish in advance any measures provide interested persons opportunities to comment complete consideration of approvals within a specified time disclose procedural rules, methodologies, principles, and criteria make available an independent review body to review determinations -whether to permit a pharmaceutical manufacturer to disseminate to health professionals and consumers through the manufacturer’s Internet site and on other linked sites information regarding its products -How to encourage ethical business practices <MRA> -Mutual Recognition Agreement on the Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) inspection of pharmaceuticals within specified period of time -Mutual Recognition of Marketing approval of generic drugs <Biogenerics> -Development of regulations related to the approval of biogenerics within specified period of time <Committee> -Whether to establish a technical committee or working group and its scope of authority <IPR Protection> -scope of guaranteeing data exclusivity -whether to permit linkage between patent and marketing approval -whether to permit use of patented product to generate information necessary to support an application for marketing approval (Bolar provision) -whether to allow adjustment of patent term to compensate unreasonable delay in marketing approval procedure -scope of compulsory licensing For a successful conclusion of negotiations, a package deal among the above core issues is necessary. Given the political sensitivity and high priority of DERP to Korea and its national interest, Korea must make certain concessions in IPR issues and Committee issues in order to accomplish its policy aims regarding DERP. Also, it must be considered that enhance protection of IPR may give certain incentives of R&D for Korean drug manufacturers who need a long-term business strategy of development. Although MRA and Biogenerics are ambitious proposals by Korea, they are susceptible to an unbalance-of-benefit claim by the United States because those proposals are focused on trade in generic (not original) drugs. In order to avoid a situation where drug issues are compelled to be traded with other unsolved controversial issues in other sectors at the last phase of negotiations, both sides must make sincere efforts to reach an early agreement through practical gives-and-takes.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
의약품 판매허가를 위한 특허발명의 시험적 실시행위와 특허권의 침해
지식재산연구
2008 .12
-
실거래가상환제의 재검토
행정법연구
2009 .08
-
한미 FTA 의약품 허가-특허 연계제도 도입으로 인한 관련법 개정 및 그 영향에 관한 고찰
법학연구
2015 .04
-
지식재산권 이론을 통해 본 한중일 FTA 협상 시의 시사점
국제정치연구
2012 .12
-
의약품 허가-특허 연계제도에 도입에 따른 시사점: KORUS FTA를 중심으로
홍익법학
2011 .01
-
한미FTA 속의 TRIPs-Plus
국제법학회논총
2008 .08
-
의약법상 자료독점권에 관한 고찰
행정법연구
2009 .12
-
Drug Situation and Drug Control in Korea
형사정책연구
1994 .09
-
실거래가상환제의 건강보험재정에 대한 영향
보건행정학회지
2005 .01
-
일본의 건강보험 약가 산정기준에 관한 연구
한국병원경영학회지
2009 .01
-
허가-특허 연계와 건강보험 : 혁신의 촉진과 공적재원의 손실방지를 위한 제도적 보완
한국사회정책
2016 .12
-
신약도입에 따른 약품비 증가요인 분석
보건경제와 정책연구
2011 .01
-
한국 제약산업의 한ㆍ미 FTA 대응 전략
무역학회지
2009 .06
-
의약품 보험급여 결정을 위한 경제성평가 연구의 평가
보건행정학회지
2005 .01
-
신약 승인 절차의 영향요인에 관한 연구
보건경제와 정책연구
2007 .01
-
마약류 수요억제 및 마약류 사범 처우합리화를 위한 종합대책
형사정책연구원 연구총서
2005 .12
-
论FTA与知识产权关系之协调
중국법연구
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0